You searched for Antibody candidate

News and Trends 7 Feb 2023

Antibody candidate for treating serious liver disease

There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people with type 2 diabetes and which can result in other serious liver diseases. However, a new study led by researchers from Karolinska Institutet in Sweden has identified a drug candidate for the treatment of fatty liver. The preclinical study, published […]

February 7, 2023 - 4 minutesmins - By Jim Cornall

Best in Biotech 8 Feb 2024

Fourteen biotech companies spearheading the antibody drug conjugate industry

The antibody-drug conjugate market has gained significant traction recently. Discover some of the top ADC companies in the industry.

February 8, 2024 - 18 minutesmins - By Jules Adam

News and Trends 27 Jul 2023

Epsilogen completes first clinical trial of IgE antibody to treat cancer

Epsilogen, a producer of immunoglobulin E (IgE) antibodies to treat cancer, has published the final phase I data from the first ever clinical trial of an IgE antibody therapeutic. The results were published in Nature Communications. MOv18 IgE is Epsilogen’s lead IgE antibody drug candidate and binds to anti-folate receptor (FRα), a well validated target […]

July 27, 2023 - 2 minutesmins - By Jim Cornall

In Depth 26 Jul 2023

Antibody drug conjugates: BiVictriX drives a new era in cancer medicine

The first-ever antibody-drug conjugate (ADC) to be approved, gemtuzumab ozogamicin, raised hope for a new class of drugs to treat cancer. But the drug was then withdrawn following a black box warning after patients experienced adverse side effects, and there had been fatalities. But this didn’t discourage biopharmas looking to create safer alternatives from expediting […]

July 26, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 22 Jun 2023

Alchemab Therapeutics unveils Alzheimer’s candidate

Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, has unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate, at the Antibody Industrial Symposium in Tours, France. ATLX-1088 is a potential first-in-class human antibody targeting CD33, a cell surface protein thought to have a key role in Alzheimer’s disease. […]

June 22, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 20 Jun 2023

Clearance for anti-tumor bispecific antibody trial

TG ImmunoPharma Co., Ltd. (TGI), which focuses on the development of novel immuno-oncology therapies, says the FDA has granted clearance for the clinical trial of TGI-6, its bispecific antibody. TGI-6 targets unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, enabling potent anti-tumor responses. TGI said the antibody demonstrates exceptional anti-tumor activity, favorable safety profiles, and […]

June 20, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. have entered into exclusive license and collaboration agreements for two antibody-drug conjugate (ADC) assets to develop, manufacture and commercialize the two assets globally, excluding mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. With this collaboration, ADCs will become an additional drug class in […]

April 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Mar 2023

OncoC4 and BioNTech partner in the commercialization of cancer drug candidate

German biopharma BioNTech has closed a licensing deal with the U.S.-based clinical-stage company OncoC4 for the development and commercialization of the latter’s lead candidate ONC-392, for the treatment of cancer. OncoC4 will receive $200 million upfront, and the transaction is expected to be completed in the first half of 2023. The company will also be […]

March 23, 2023 - 2 minutesmins - By Roohi Mariam Peter

antibody drug conjugate adc small cancer treatment

News and Trends 23 Dec 2022

Merck and Kelun-Biotech collaborating on seven ADC cancer candidates

Merck (MSD outside of the U.S. and Canada), and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer. “Advances in ADC technologies are yielding a new generation of candidates designed to more […]

December 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Dec 2022

Positive antibody persistence for vaccine treating mosquito disease

A single shot vaccine for mosquito-borne disease chikungunya has had positive antibody persistence data 12 months after vaccination. The primary endpoint also met with a 99% seroresponse rate. The disease is caused by the chikungunya virus (CHIKV), a Togaviridae virus, transmitted by Aedes mosquitoes. Following positive immunogenicity and safety data from a phase 3 study […]

December 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 16 Nov 2022

Bio-Rad introduces pioneer antibody discovery platform for therapeutic development

Bio-Rad Laboratories Inc. yesterday (November 15) announced the launch of its Pioneer Platform, a new antibody discovery service specifically designed to develop biologic candidates. The Pioneer Platform features a phage display library engineered to include more than 200 billion unique sequences and capable of identifying high-affinity antibody candidates using Bio-Rad’s newly developed SpyDisplay selection technology. […]

November 16, 2022 - 2 minutesmins - By Liza Laws

News and Trends 20 Oct 2022

Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market

Alvotech and the JAMP Pharma Group have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech. The companies have added two biosimilar candidates from Alvotech’s pipeline: AVT16, a proposed biosimilar to an undisclosed immunology product and AVT33, a proposed biosimilar to an undisclosed oncology product. “We are very pleased to be expanding […]

October 20, 2022 - 2 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us